ada standards of care 2025 glp-1 receptor agonists recommendations Diabetes (2025) - Guidelines Spotlight ADA Updates Diabetes Treatment Guidelines

Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

THURSDAY, Dec

From weight loss breakthroughsto type 2 diabetes management, and even anti-aging medicine, these treatments offer extraordinary promise.But with innovation comes risk

To overcome this limitation, various modifications and delivery strategies to enhance the pharmacokinetic properties and therapeutic efficacy of GLP-1 analogs have been studied